Evidence map›Paper›PMID 38171875›Full record

ReviewInternal medicine (Tokyo, Japan)2024

An Elderly Patient Developed Ulcerative Colitis after SARS-CoV-2 mRNA Vaccination: A Case Report and Review of the Literature.

Takahito Shimada, Jun Takada, Atsushi Baba, Masahide Iwashita, Takao Hayashi, Teruo Maeda, Masahito Shimizu

Open access · diamondAbstract readReviewCase Reports
In one paragraph

Review in Internal medicine (Tokyo, Japan), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Takahito ShimadaDepartment of Internal Medicine, JA Gifu Koseiren Gifu/Seino Medical Center Nishimino Kosei Hospital, Japan.
Jun TakadaDepartment of Gastroenterology, Gifu University Graduate School of Medicine, Japan.
Atsushi BabaDepartment of Internal Medicine, JA Gifu Koseiren Gifu/Seino Medical Center Nishimino Kosei Hospital, Japan.
Masahide IwashitaDepartment of Internal Medicine, JA Gifu Koseiren Gifu/Seino Medical Center Nishimino Kosei Hospital, Japan.
Takao HayashiDepartment of Internal Medicine, JA Gifu Koseiren Gifu/Seino Medical Center Nishimino Kosei Hospital, Japan.
Teruo MaedaDepartment of Internal Medicine, JA Gifu Koseiren Gifu/Seino Medical Center Nishimino Kosei Hospital, Japan.
Masahito ShimizuDepartment of Gastroenterology, Gifu University Graduate School of Medicine, Japan.
Gifu University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An 86-year-old man presented to our hospital with symptoms of diarrhea and bloody stool, which had manifested two weeks after receiving his third severe acute respiratory syndrome coronavirus 2 mRNA vaccination. Colonoscopy revealed diffuse, rough-surfaced mucosa extending from the ascending colon to the rectum. Despite attempting probiotic treatment, the patient's condition did not improve, leading to admission. Endoscopic findings at admission worsened. Based on endoscopic and histopathological findings, the patient was diagnosed with ulcerative colitis. Corticosteroids and 5-aminosalicylic acid were administered, and the clinical symptoms improved. Subsequently, the disease worsened during steroid tapering, and filgotinib was added, leading to steroid-free remission.

Indexed as

Colitis, UlcerativeCOVID-19AgedAged, 80 and overHumansMaleRNA, MessengerSARS-CoV-2VaccinationRNA, Messengeradverse eventelderly patientinflammatory bowel diseaseSARS-CoV-2 mRNA vaccineulcerative colitis

Identifiers

PMID38171875
PMCPMC11009001
OpenAlexW4390479950

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.